X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4021) 4021
Book Review (814) 814
Publication (281) 281
Newsletter (114) 114
Newspaper Article (74) 74
Magazine Article (26) 26
Conference Proceeding (10) 10
Book Chapter (9) 9
Transcript (6) 6
Dissertation (2) 2
Book / eBook (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3412) 3412
humans (2973) 2973
multiple sclerosis (1689) 1689
female (1580) 1580
male (1406) 1406
adult (1192) 1192
interferon-beta - therapeutic use (1185) 1185
animals (1092) 1092
interferon-beta - administration & dosage (1042) 1042
interferon-beta (1031) 1031
interferon beta (1019) 1019
middle aged (904) 904
clinical neurology (862) 862
multiple sclerosis - drug therapy (859) 859
interferon (791) 791
interferon beta-1a (715) 715
mice (712) 712
immunology (693) 693
neurosciences (640) 640
biological response modifiers (628) 628
treatment outcome (626) 626
multiple sclerosis, relapsing-remitting - drug therapy (546) 546
interferon-beta - adverse effects (471) 471
interferon beta-1b (454) 454
glatiramer acetate (444) 444
double-blind (436) 436
pharmacology & pharmacy (430) 430
neurology (426) 426
care and treatment (411) 411
therapy (411) 411
research (400) 400
drug therapy (396) 396
interferon-beta - pharmacology (368) 368
adjuvants, immunologic - administration & dosage (343) 343
magnetic resonance imaging (342) 342
health aspects (340) 340
abridged index medicus (323) 323
interferon-beta - immunology (314) 314
adjuvants, immunologic - therapeutic use (308) 308
multiple sclerosis - immunology (307) 307
adolescent (296) 296
time factors (294) 294
aged (293) 293
interferon-beta - genetics (279) 279
disease progression (278) 278
placebo-controlled trial (277) 277
interferon-beta - metabolism (276) 276
immunologic factors - therapeutic use (269) 269
multiple-sclerosis (266) 266
expression (263) 263
oncology (258) 258
drug administration schedule (255) 255
cytokines (253) 253
dose-response relationship, drug (247) 247
mice, inbred c57bl (245) 245
analysis (242) 242
medicine & public health (242) 242
ifn-beta (241) 241
inflammation (235) 235
dosage and administration (233) 233
immunosuppressive agents - therapeutic use (227) 227
biochemistry & molecular biology (226) 226
cell biology (226) 226
neutralizing antibodies (219) 219
disease (216) 216
medicine, research & experimental (212) 212
follow-up studies (211) 211
multicenter (204) 204
drug therapy, combination (203) 203
experimental autoimmune encephalomyelitis (203) 203
injections, subcutaneous (198) 198
multiple sclerosis - therapy (196) 196
central-nervous-system (192) 192
gene expression (192) 192
young adult (192) 192
interferon-β (191) 191
cells, cultured (189) 189
disability (187) 187
cancer (183) 183
research article (183) 183
cells (180) 180
dendritic cells (180) 180
disability evaluation (180) 180
medicine (179) 179
immunotherapy (178) 178
recurrence (177) 177
activation (171) 171
adjuvants, immunologic - adverse effects (171) 171
natalizumab (169) 169
proteins (169) 169
clinical trials (168) 168
peptides - therapeutic use (168) 168
medicine, general & internal (163) 163
efficacy (159) 159
injections, intramuscular (159) 159
t-cells (158) 158
medical research (155) 155
article (154) 154
alpha (153) 153
cell line, tumor (152) 152
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4015) 4015
Japanese (62) 62
German (55) 55
French (28) 28
Russian (20) 20
Spanish (18) 18
Italian (11) 11
Hungarian (9) 9
Polish (9) 9
Swedish (4) 4
Chinese (3) 3
Danish (3) 3
Norwegian (2) 2
Czech (1) 1
Finnish (1) 1
Hebrew (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuroscience, ISSN 0306-4522, 2008, Volume 152, Issue 3, pp. 785 - 797
Abstract We determined the nervous system targeting of interferon-β1b (IFN-β1b), a 20 kDa protein used to treat the relapsing–remitting form of multiple... 
Neurology | olfactory system | trigeminal system | blood–brain barrier | basal ganglia | drug delivery | multiple sclerosis | blood-brain barrier | HUMAN-LEUKOCYTE INTERFERON | DENDRITIC CELLS | CEREBROSPINAL-FLUID | BLOOD-BRAIN-BARRIER | ALPHA-INTERFERON | NEUROSCIENCES | MULTIPLE-SCLEROSIS | TISSUE DISTRIBUTION | CERVICAL LYMPH-NODES | GROWTH-FACTOR-I | TRANSGENIC MICE | Trigeminal Nerve - metabolism | Iodine Radioisotopes | Interferon-beta - pharmacokinetics | Nervous System - metabolism | Basal Ganglia - metabolism | Extracellular Space - drug effects | Male | Olfactory Mucosa - metabolism | Olfactory Bulb - metabolism | Immunologic Factors - pharmacokinetics | Extracellular Space - metabolism | Protein Binding - drug effects | Radioimmunoassay | Macaca | Nervous System - immunology | Interferon-beta - administration & dosage | Receptors, Interferon - drug effects | Immunologic Factors - administration & dosage | Administration, Intranasal | Blood-Brain Barrier - drug effects | Extracellular Fluid - drug effects | Blood-Brain Barrier - metabolism | Receptors, Interferon - metabolism | Autoradiography | Extracellular Fluid - metabolism | Trigeminal Nerve - drug effects | Animals | Interferon-beta - metabolism | Nervous System - drug effects | Brain Mapping | Immunologic Factors - metabolism | Olfactory Bulb - drug effects | Olfactory Mucosa - drug effects | Basal Ganglia - drug effects | Protein Binding - physiology | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9856, pp. 1819 - 1828
Journal Article
Lancet, The, ISSN 0140-6736, 11/2012, Volume 380, Issue 9856, pp. 1829 - 1839
Journal Article
Biomaterials, ISSN 0142-9612, 2011, Volume 32, Issue 36, pp. 9888 - 9898
Journal Article
Pharmacological Research, ISSN 1043-6618, 2009, Volume 60, Issue 4, pp. 207 - 211
Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological... 
Multiple sclerosis | Immunosuppression | Injectables | Immunomodulation | Oral therapy | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | LAQUINIMOD ABR-215062 | ORAL FINGOLIMOD FTY720 | PROGRESSIVE MS | CONTROLLED PHASE IIB | CLADRIBINE | SPHINGOSINE 1-PHOSPHATE RECEPTORS | IMMUNOMODULATOR | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | DISEASE-MODIFYING THERAPIES | Antibodies, Neoplasm - therapeutic use | Injections, Intravenous | Humans | Antibodies, Monoclonal - therapeutic use | Fumarates - administration & dosage | Toluidines - administration & dosage | Interferon-beta - therapeutic use | Antibodies, Monoclonal, Humanized | Sphingosine - administration & dosage | Injections, Subcutaneous | Propylene Glycols - therapeutic use | Quinolones - therapeutic use | Crotonates - administration & dosage | Interferon-beta - administration & dosage | Toluidines - therapeutic use | Administration, Oral | Fumarates - therapeutic use | Immunologic Factors - administration & dosage | Fingolimod Hydrochloride | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Cladribine - administration & dosage | Crotonates - therapeutic use | Quinolones - administration & dosage | Sphingosine - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Propylene Glycols - administration & dosage | Cladribine - therapeutic use | Sphingosine - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Monoclonal antibodies | Immunotherapy | Index Medicus
Journal Article
Journal Article
Neurology, ISSN 0028-3878, 04/2012, Volume 78, Issue 15, pp. 1179 - 1185
Journal Article
Scientific Reports, ISSN 2045-2322, 04/2014, Volume 4, Issue 1, pp. 4638 - 4638
Journal Article